The possible role of gastrin-releasing peptide on pulmonary fibrosis

Ö. Kayalar (Istanbul, Turkey), H. Öngen (Istanbul, Turkey), F. Oztay (Istanbul, Turkey)

Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Session: Pulmonary fibrosis: from models to patients
Session type: Thematic Poster
Number: 1003
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Ö. Kayalar (Istanbul, Turkey), H. Öngen (Istanbul, Turkey), F. Oztay (Istanbul, Turkey). The possible role of gastrin-releasing peptide on pulmonary fibrosis. 1003

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 111s
Year: 2004

Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets
Source: Eur Respir J 2006; 28: Suppl. 50, 659s
Year: 2006

The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis.
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019

Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018



Prognostic value of serum N-terminal brain natriuretic peptide type B for pulmonary hypertension among patients with usual interstitial pneumonia and sarcoidosis
Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases
Year: 2007


Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008

Remarkable induction of brain natriuretic peptide in pulmonary emphysema after acute respiratory infection
Source: Eur Respir J 2006; 28: Suppl. 50, 408s
Year: 2006

N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2005; 25: 509-513
Year: 2005



Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006


Diffusing lung capacity and pro-brain natriuretic peptide in patients with limited cutaneous form of systemic sclerosis at risk for pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism
Source: Eur Respir J 2003 Oct 01;22(4):649-653
Year: 2003



Correlation of levels of N-terminal pro-B-type natriuretic peptide with localization of thrombus in acute pulmonary embolism
Source: Annual Congress 2011 - Clinical features of pulmonary thromboembolism
Year: 2011

The utility of brain natriuretic peptide in patients with stable chronic lung diseases
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012


N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pulmonary hypertension and renal insufficiency
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013


Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension
Source: Eur Respir J 2010; 35: 95-104
Year: 2010



Comparison of brain natriuretic peptide to n-terminal pro brain natriuretic peptide in idiopathic interstitial pneumonia
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009


Role of B-type brain natriuretic peptide in the development of fluid retention and detection of right ventricular failure in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 305s
Year: 2004

The role of antimicrobial peptides in cystic fibrosis in childhood.
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019


Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006


Brain natriuretic peptide in patients with acute pulmonary embolism
Source: Eur Respir J 2005; 26: Suppl. 49, 270s
Year: 2005